Postoperative lymphocele causing obturator nerve entrapment, treated with percutaneous drainage and intranodal poppyseed oil (Lipiodol)-based lymphangiography.

Obturator nerve entrapment is a rare complication after pelvic surgery and is caused by a direct intraoperative injury or secondary to compression by a postoperative collection. We have presented the case of a 65-year-old man who had complained of right-sided medial groin pain 4 weeks after robot-assisted laparoscopic prostatectomy with bilateral pelvic lymphadenectomy. Pelvic magnetic resonance imaging showed bilateral lymphoceles with right-sided compression of the obturator nerve causing diffuse muscle edema in its innervation region.

Using single-plant-omics in the field to link maize genes to functions and phenotypes.

Most of our current knowledge on plant molecular biology is based on experiments in controlled laboratory environments. However, translating this knowledge from the laboratory to the field is often not straightforward, in part because field growth conditions are very different from laboratory conditions. Here, we test a new experimental design to unravel the molecular wiring of plants and study gene-phenotype relationships directly in the field.

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis.

Background: There are multiple existing and emerging therapeutic avenues for metastatic prostate cancer, with a common denominator, which is the need for predictive biomarkers. Circulating tumor DNA (ctDNA) has the potential to cost-efficiently accelerate precision medicine trials to improve clinical efficacy and diminish costs and toxicity. However, comprehensive ctDNA profiling in metastatic prostate cancer to date has been limited.

Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer.

Purpose: To infer the prognostic value of simultaneous androgen receptor () and profiling in liquid biopsies from patients with metastatic castration-resistant prostate cancer (mCRPC) starting a new line of signaling inhibitors (ARSi). Between March 2014 and April 2017, we recruited patients with mCRPC ( = 168) prior to ARSi in a cohort study encompassing 10 European centers. Blood samples were collected for comprehensive profiling of CellSearch-enriched circulating tumor cells (CTC) and circulating tumor DNA (ctDNA).